Intermittent  ||| S:0 E:13 ||| JJ
hypoxia ||| S:13 E:20 ||| NN
:  ||| S:20 E:22 ||| :
a  ||| S:22 E:24 ||| DT
low-risk  ||| S:24 E:33 ||| JJ
research  ||| S:33 E:42 ||| NN
tool  ||| S:42 E:47 ||| NN
with  ||| S:47 E:52 ||| IN
therapeutic  ||| S:52 E:64 ||| JJ
value  ||| S:64 E:70 ||| NN
in  ||| S:70 E:73 ||| IN
humans  ||| S:73 E:80 ||| NNS
Intermittent  ||| S:80 E:93 ||| JJ
hypoxia  ||| S:93 E:101 ||| NN
has  ||| S:101 E:105 ||| VBZ
generally  ||| S:105 E:115 ||| RB
been  ||| S:115 E:120 ||| VBN
perceived  ||| S:120 E:130 ||| VBN
as  ||| S:130 E:133 ||| IN
a  ||| S:133 E:135 ||| DT
high-risk  ||| S:135 E:145 ||| JJ
stimulus ||| S:145 E:153 ||| NN
,  ||| S:153 E:155 ||| ,
particularly  ||| S:155 E:168 ||| RB
in  ||| S:168 E:171 ||| IN
the  ||| S:171 E:175 ||| DT
field  ||| S:175 E:181 ||| NN
of  ||| S:181 E:184 ||| IN
sleep  ||| S:184 E:190 ||| JJ
medicine ||| S:190 E:198 ||| NN
,  ||| S:198 E:200 ||| ,
because  ||| S:200 E:208 ||| IN
it  ||| S:208 E:211 ||| PRP
is  ||| S:211 E:214 ||| VBZ
thought  ||| S:214 E:222 ||| VBN
to  ||| S:222 E:225 ||| TO
initiate  ||| S:225 E:234 ||| VB
detrimental  ||| S:234 E:246 ||| JJ
cardiovascular ||| S:246 E:260 ||| NN
,  ||| S:260 E:262 ||| ,
respiratory ||| S:262 E:273 ||| NN
,  ||| S:273 E:275 ||| ,
cognitive ||| S:275 E:284 ||| NN
,  ||| S:284 E:286 ||| ,
and  ||| S:286 E:290 ||| CC
metabolic  ||| S:290 E:300 ||| JJ
outcomes ||| S:300 E:308 ||| NNS
.  ||| S:308 E:310 ||| .
In  ||| S:310 E:313 ||| IN
contrast ||| S:313 E:321 ||| NN
,  ||| S:321 E:323 ||| ,
the  ||| S:323 E:327 ||| DT
link  ||| S:327 E:332 ||| NN
between  ||| S:332 E:340 ||| IN
intermittent  ||| S:340 E:353 ||| JJ
hypoxia  ||| S:353 E:361 ||| NN
and  ||| S:361 E:365 ||| CC
beneficial  ||| S:365 E:376 ||| JJ
outcomes  ||| S:376 E:385 ||| NN
has  ||| S:385 E:389 ||| VBZ
received  ||| S:389 E:398 ||| VBN
less  ||| S:398 E:403 ||| JJR
attention ||| S:403 E:412 ||| NN
,  ||| S:412 E:414 ||| ,
perhaps  ||| S:414 E:422 ||| RB
because  ||| S:422 E:430 ||| IN
it  ||| S:430 E:433 ||| PRP
is  ||| S:433 E:436 ||| VBZ
not  ||| S:436 E:440 ||| RB
universally  ||| S:440 E:452 ||| RB
understood  ||| S:452 E:463 ||| VBN
that  ||| S:463 E:468 ||| IN
outcome  ||| S:468 E:476 ||| NN
measures  ||| S:476 E:485 ||| VBZ
following  ||| S:485 E:495 ||| VBG
exposure  ||| S:495 E:504 ||| NN
to  ||| S:504 E:507 ||| TO
intermittent  ||| S:507 E:520 ||| JJ
hypoxia  ||| S:520 E:528 ||| NN
may  ||| S:528 E:532 ||| MD
be  ||| S:532 E:535 ||| VB
linked  ||| S:535 E:542 ||| VBN
to  ||| S:542 E:545 ||| TO
the  ||| S:545 E:549 ||| DT
administered  ||| S:549 E:562 ||| JJ
dose ||| S:562 E:566 ||| NN
.  ||| S:566 E:568 ||| .
The  ||| S:568 E:572 ||| DT
present  ||| S:572 E:580 ||| JJ
review  ||| S:580 E:587 ||| NN
is  ||| S:587 E:590 ||| VBZ
designed  ||| S:590 E:599 ||| VBN
to  ||| S:599 E:602 ||| TO
emphasize  ||| S:602 E:612 ||| VB
the  ||| S:612 E:616 ||| DT
less  ||| S:616 E:621 ||| RBR
recognized  ||| S:621 E:632 ||| VBN
beneficial  ||| S:632 E:643 ||| JJ
outcomes  ||| S:643 E:652 ||| NNS
associated  ||| S:652 E:663 ||| VBN
with  ||| S:663 E:668 ||| IN
intermittent  ||| S:668 E:681 ||| JJ
hypoxia ||| S:681 E:688 ||| NN
.  ||| S:688 E:690 ||| .
The  ||| S:690 E:694 ||| DT
review  ||| S:694 E:701 ||| NN
will  ||| S:701 E:706 ||| MD
consider  ||| S:706 E:715 ||| VB
the  ||| S:715 E:719 ||| DT
role  ||| S:719 E:724 ||| NN
intermittent  ||| S:724 E:737 ||| JJ
hypoxia  ||| S:737 E:745 ||| NN
has  ||| S:745 E:749 ||| VBZ
in  ||| S:749 E:752 ||| IN
cardiovascular  ||| S:752 E:767 ||| JJ
and  ||| S:767 E:771 ||| CC
autonomic  ||| S:771 E:781 ||| JJ
adaptations ||| S:781 E:792 ||| NN
,  ||| S:792 E:794 ||| ,
respiratory  ||| S:794 E:806 ||| JJ
motor  ||| S:806 E:812 ||| NN
plasticity ||| S:812 E:822 ||| NN
,  ||| S:822 E:824 ||| ,
and  ||| S:824 E:828 ||| CC
cognitive  ||| S:828 E:838 ||| JJ
function ||| S:838 E:846 ||| NN
.  ||| S:846 E:848 ||| .
Each  ||| S:848 E:853 ||| DT
section  ||| S:853 E:861 ||| NN
will  ||| S:861 E:866 ||| MD
highlight  ||| S:866 E:876 ||| VB
the  ||| S:876 E:880 ||| DT
literature  ||| S:880 E:891 ||| NN
that  ||| S:891 E:896 ||| WDT
contributed  ||| S:896 E:908 ||| VBD
to  ||| S:908 E:911 ||| TO
the  ||| S:911 E:915 ||| DT
belief  ||| S:915 E:922 ||| NN
that  ||| S:922 E:927 ||| IN
intermittent  ||| S:927 E:940 ||| JJ
hypoxia  ||| S:940 E:948 ||| NN
leads  ||| S:948 E:954 ||| VBZ
primarily  ||| S:954 E:964 ||| RB
to  ||| S:964 E:967 ||| TO
detrimental  ||| S:967 E:979 ||| VB
outcomes ||| S:979 E:987 ||| NNS
.  ||| S:987 E:989 ||| .
The  ||| S:989 E:993 ||| DT
second  ||| S:993 E:1000 ||| JJ
segment  ||| S:1000 E:1008 ||| NN
of  ||| S:1008 E:1011 ||| IN
each  ||| S:1011 E:1016 ||| DT
section  ||| S:1016 E:1024 ||| NN
will  ||| S:1024 E:1029 ||| MD
consider  ||| S:1029 E:1038 ||| VB
the  ||| S:1038 E:1042 ||| DT
possible  ||| S:1042 E:1051 ||| JJ
risks  ||| S:1051 E:1057 ||| NNS
associated  ||| S:1057 E:1068 ||| VBN
with  ||| S:1068 E:1073 ||| IN
experimentally  ||| S:1073 E:1088 ||| RB
rather  ||| S:1088 E:1095 ||| RB
than  ||| S:1095 E:1100 ||| IN
naturally  ||| S:1100 E:1110 ||| RB
induced  ||| S:1110 E:1118 ||| VBN
intermittent  ||| S:1118 E:1131 ||| JJ
hypoxia ||| S:1131 E:1138 ||| NN
.  ||| S:1138 E:1140 ||| .
Finally ||| S:1140 E:1147 ||| RB
,  ||| S:1147 E:1149 ||| ,
the  ||| S:1149 E:1153 ||| DT
body  ||| S:1153 E:1158 ||| NN
of  ||| S:1158 E:1161 ||| IN
literature  ||| S:1161 E:1172 ||| NN
indicating  ||| S:1172 E:1183 ||| VBG
that  ||| S:1183 E:1188 ||| IN
intermittent  ||| S:1188 E:1201 ||| JJ
hypoxia  ||| S:1201 E:1209 ||| NNS
initiates  ||| S:1209 E:1219 ||| VBP
primarily  ||| S:1219 E:1229 ||| RB
beneficial  ||| S:1229 E:1240 ||| JJ
outcomes  ||| S:1240 E:1249 ||| NNS
will  ||| S:1249 E:1254 ||| MD
be  ||| S:1254 E:1257 ||| VB
considered ||| S:1257 E:1267 ||| VBN
.  ||| S:1267 E:1269 ||| .
The  ||| S:1269 E:1273 ||| DT
overarching  ||| S:1273 E:1285 ||| JJ
theme  ||| S:1285 E:1291 ||| NN
of  ||| S:1291 E:1294 ||| IN
the  ||| S:1294 E:1298 ||| DT
review  ||| S:1298 E:1305 ||| NN
is  ||| S:1305 E:1308 ||| VBZ
that  ||| S:1308 E:1313 ||| IN
the  ||| S:1313 E:1317 ||| DT
use  ||| S:1317 E:1321 ||| NN
of  ||| S:1321 E:1324 ||| IN
intermittent  ||| S:1324 E:1337 ||| JJ
hypoxia  ||| S:1337 E:1345 ||| NN
in  ||| S:1345 E:1348 ||| IN
research  ||| S:1348 E:1357 ||| NN
investigations ||| S:1357 E:1371 ||| NNS
,  ||| S:1371 E:1373 ||| ,
coupled  ||| S:1373 E:1381 ||| VBN
with  ||| S:1381 E:1386 ||| IN
reasonable  ||| S:1386 E:1397 ||| JJ
safeguards ||| S:1397 E:1407 ||| NNS
,  ||| S:1407 E:1409 ||| ,
should  ||| S:1409 E:1416 ||| MD
be  ||| S:1416 E:1419 ||| VB
encouraged  ||| S:1419 E:1430 ||| VBN
because  ||| S:1430 E:1438 ||| IN
of  ||| S:1438 E:1441 ||| IN
the  ||| S:1441 E:1445 ||| DT
potential  ||| S:1445 E:1455 ||| JJ
benefits  ||| S:1455 E:1464 ||| NNS
linked  ||| S:1464 E:1471 ||| VBN
to  ||| S:1471 E:1474 ||| TO
the  ||| S:1474 E:1478 ||| DT
administration  ||| S:1478 E:1493 ||| NN
of  ||| S:1493 E:1496 ||| IN
a  ||| S:1496 E:1498 ||| DT
variety  ||| S:1498 E:1506 ||| NN
of  ||| S:1506 E:1509 ||| IN
low-risk  ||| S:1509 E:1518 ||| JJ
intermittent  ||| S:1518 E:1531 ||| JJ
hypoxia  ||| S:1531 E:1539 ||| JJ
protocols ||| S:1539 E:1548 ||| NNS
.  ||| S:1548 E:1550 ||| .
